Agarwal Group of Eye Hospitals Raises Rs. 270 Crore Funding from Temasek
Dr. Agarwal Group of Eye Hospitals Raises Rs. 270 Crore Funding from Temasek press release for your kind perusal.
Dr. Agarwal Group of Eye Hospitals Raises Rs. 270 Crore Funding from Temasek
Chennai, 13th February 2019: Dr. Agarwal’s Healthcare Ltd. (DAHCL) has raised Rs. 270 crore investment from Temasek, a global investment company headquartered in Singapore. The investment will be used to expand the Indian geographical footprint of the international eye care chain, along with significant investments in latest tec hnology for super specialty eye-care.
Temasek is a global investor anchored in Asia, with India accounting for around 4% of its S$308 billion (US$ 23 5b) portfolio as at 31 March 2018. Temasek‘s healthcare portfolio in India includes investments in Medanta MediCity, Manipal Hospitals and HealthCare Global.
L to R: Dr. Adil Agarwal, CEO, Dr. Agarwal’s Group of Eye Hospitals and Prof. (Dr.) Amar Agarwal, (MS, FRCS, FRC Ophth), Chairman, Dr. Agarwal’s Group of Eye Hospitals addressing the media today
“The Agarwal Group is excited to welcome Temasek as an investor. We believe their expertise and support will help our company expand our network of clinics and operations to better meet the growing demand for affor dable and quality eye care across India.” said Prof. (Dr.) Amar Agarwal, (MS, FRCS, FRC Ophth), Chairman, Dr. Agarwal’s Group of Eye Hospitals.
Dr. Adil Agarwal, CEO, Dr. Agarwal’s Group of Eye Hospitals said that “We are looking at adding anywhere bet ween 50-75 hospitals to our network over the next 3-5 years with a major focus on metro cities as well as tier 2 and tier 3 towns. The expansion will be done through a mix of strategic partnerships, acquisitions and greenfield hospitals. Innovation and technology will continue to be at the forefront of our growth, and we will be investing more in cutting edge technology such as SMILE, FemtoLaser and Robotic Cataract Surgery across our centers. Ou r aim is to deliver high quality eye care at affordable prices at people’s doorsteps”.
Veda Corporate Advisors, a leading mid-market investment bank advised the Company on the transaction. Veda also advised the Company on its previous round of investment from ADV Partners.
The Dr Agarwal Eye Hospital group has been at the forefront of innovation in the field of Ophthalmology with procedures such as Glued IOL (to treat patients with complicated lens problems), PDEK (an ultra-modern form of Corneal transplants) and PhakoNIT (Removal of Cataract through a sub 1mm incision). The latest invention from the group is a novel technique called “Single-Pass Four Throw” (SFT) along with “Pin Hole Pupilloplasty”, whi ch is also referred to as PPP. The surgical technique is being used to help in pupillary reconstruction as well as to treat complicated cases of Narrow Angle Glaucoma. There is also a lot of focus on education and training and the group attracts doctors from across the globe for its training programs; They also offer a DNB (post grad uate) program and various fellowship programs to train young, budding surgeons.
“ADV welcomes Temasek as a new partner in Dr Agarwal’s growth story; this investment will further strengthen the company’s leadership position in India’s eye-care ecosystem” said Mr. Suresh Prabhala, Co-founder, ADV Par tners. ADV Partners invested Rs 270 crores in Dr Agarwal’s HealthCare Ltd in 2016 and has been a key com pon ent of the company’s board and growth story.
About Dr Agarwal
Dr. Agarwal’s Group of Eye Hospitals started as a single facility in Chennai in the year 1957. Now the hospital chain has a total presence of 76 hospitals with 63 centres in India (across 13 states) and 12 hospitals in Africa (across 10 countries). A tertiary eye care center set up at Mauritius in 2010 marked its entry into the intern ati onal market.
The group offers a complete gamut of eye care services such as Cataract, Laser correction, Vitreo-Retinal Su rgery, Corneal transplantation, Glaucoma and Squint at its centers. In addition to this, super-specialty eye care services such as Pediatric ophthalmology, Ocular Oncology, Neuro ophthalmology, Uvea and Oculoplasty are al so offered at its tertiary hubs.
Incorporated in 1974, Temasek is a global investment company headquartered in Singapore. Supported by our network of international offices, Temasek owns a S$308 billion (US$235b) portfolio as at 31 March 2018, with significant exposure to Singapore and the rest of Asia.Our investment activities are guided by four investment themes and the long term trends they represent: Transforming Economies; Growing Middle Income Populations; Deepening Comparative Advantages; and Emerging Champions.Our investment strategy allows us to capture opportunities across the sectors in which we invest that help bring about a better, smarter and more connected world.We actively seek sustainable solutions to address present and future challenges. Across the three pillars of the Temasek Charter, we recognise the need to do well as an investor; to do right as an institution; and to do good as a steward.
For more information on Temasek, please visit www.temasek.com.sg
For the latest Temasek Review, please visit www.temasekreview.com.sg
Connect with us on social media: Facebook (Temasek); Twitter (@Temasek); Instagram (@temasekseen) and LinkedIn (Temasek)